

# Efficacy of Plasma microRNA-143 and microRNA-550a as Potential Diagnostic and Prognostic Biomarkers for Chronic Hepatitis and Hepatocellular Carcinoma in Egyptian Patients

Shadia AH Fathy<sup>1</sup>, Manal A Emam<sup>1</sup>, Sara HA Agwa<sup>2</sup>, Christina A.Soliman<sup>1</sup> and Sarah El-Nakeep\*<sup>3</sup>

<sup>1</sup>Biochemistry Department, Ain Shams University, Egypt

<sup>2</sup>Medical Research Center, Ain Shams University, Egypt

<sup>3</sup>Internal Medicine Department, Shams University, Egypt

Received: January 02, 2018; Published: January 11, 2018

\*Corresponding author: Sarah El-Nakeep, Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Email: sarahnakeep@yahoo.com

## Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the leading cause of cancer death in the world. Its poor prognosis is mainly due to the late detection of the tumor, thus multiple genetic markers including micro RNAs are under research to improve detection and prognosis of HCC.

**Aim:** of this study was to evaluate the diagnostic potential of a panel of two circulating miR 143 and miR-550a as diagnostic biomarkers for hepatocellular carcinoma (HCC) among patients with hepatitis C virus (HCV) infected Egyptian.

**Methods:** A total of 81 participants were included in this study (3 controls, 41 hepatitis C patients and 37 HCC patients). Samples were collected, and both miR143 and miR-550a were assessed.

**Results:** The expression levels of the two miRNAs (miR-143 and miR-550a) were detected by quantitative reverse-transcriptase PCR (RT-qPCR) in controls, HCV and HCC patients. miR-143 showed no correlation with the two groups while miR-550a showed reversed correlation. AUC for miR550 was 0.93 (0.86-0.99) with sensitivity 91.89% and specificity 90.24% at the cutoff value  $\leq 3.29$  for prediction of HCC occurrence, and NPV was 92.5 and PPV was 89.5.

**Conclusion:** The expression of plasma miR-143 was not correlated with the occurrence of HCC while plasma miR-550a was significantly down-regulated in patients with HCC, thus it could be a good potential circulating biomarker for HCC.

**Keywords:** Hepatocellular carcinoma; hepatitis C virus; miR-143; miR-550a; HCC prognosis; HCC diagnosis

**Abbreviations:** HCC: Hepatocellular Carcinoma; CT: Computed Tomography; MRI: Magnetic Resonance Imaging; ALT: Alanine Aminotransferase; AST: Aspartate Amino-Transferase; INR: International Normalized Ratio; AFP: Alpha-Feto Protein; SPSS: Statistical Program for Social Science; AUC: Area Under Curve; ROC: Receiver Operating Characteristic

## Introduction

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer [1]. Overall, it is the fifth most common cancer worldwide, representing about 5.7% of all new human cancer cases with an increasing incidence expected in the next decade [2]. High prevalence of HCC in Egypt is mainly caused by the high prevalence in HCV; where an Egyptian cohort of HCC patients found that the prevalence of HCV was 91.32% while HBV was 2.51% in the studied population [3]. HCV related HCC is preceded by cirrhosis, in contrary to HBV where HCC is induced by the genetic mutation caused by the virus rather than its liver destruction effect by

chronic hepatitis, thus in HBV HCC could present earlier than HCV [4]. The ASLD and EASL guidelines recently removed AFP from the screening of HCC as its diagnostic efficacy is high only when there is micro-metastasis or late stage of cancer, a compelling need for early detection markers for better prognosis of HCC and rendering the patient more liable to curative measures, to improve the patients survival [5].

Curative measures for HCC patients are still limited to the early discovery of the disease and includes; liver transplantation, resection or radiofrequency [6]. MicroRNAs (miRNAs) are endogenous,

small, single-stranded, noncoding RNAs that consist of 20 to 25 bases. They control various biological functions such as cellular proliferation, differentiation and apoptosis. Approximately half of human miRNAs are located in fragile regions chromosomes, which are associated with the development of human cancers. miRNAs have been referred to as so-called oncomirs for their functions as tumor suppressors and oncogenes [6]. Aberrant expression of miRNA has been linked to a variety of cancers, including HCC [7]. In the present study, we have evaluated the possibility of using two circular HCC-related miRNAs (miR-143 and miR-550a) as possible non-invasive serum biomarkers for diagnosis and prognosis of HCV associated HCC using qT-PCR. To our knowledge, this is the first study testing mi-143 and miR-550a in plasma of for HCC, also the first to be done in Egypt.

## Methods

The study population consisted of 41 patients with Chronic Hepatitis C virus and 37 patients with HCV associated hepatocellular carcinoma who were treated at the Tropical Medicine Department and Internal Medicine Department, AinShams University Hospitals and 3 healthy normal volunteers with matching age and sex to the patients' groups after obtaining informed consent. The study was approved by AinShams Faculty of Medicine Ethical Committee. All of the HCC patients were diagnosed by triphasic contrast enhanced computed tomography (CT) scan or magnetic resonance imaging (MRI), and tested for liver functions and AFP. HCC patients with no evidence of local invasion or distant metastasis and positive for HCV were included. While patients with metastatic HCC or other forms of cancer other than HCC were excluded. Three milliliters of peripheral blood were collected from the patients and healthy controls; plasma was separated for miRNAs purification. All the samples were stored at -80 °C for extraction of RNA.

## Biochemical Analysis

Laboratory investigations included; liver function tests, alanine aminotransferase (ALT), Aspartate amino-Transferase (AST), total bilirubin, albumin, platelets count and International normalized ratio (INR) were done for all of the subjects in the study. Data of all subjects were obtained from medical records and personal history and clinical examination.

## Serum Alpha-Feto Protein Detection

Sera from chronic HCV and HCC patients were used for estimation of serum level of Alpha-feto protein (AFP) by solid phase two sequential chemiluminescent immunometric assay using immulite 2000 system analyzer, the kits were supplied by Siemens (Siemens Healthcare Diagnostics, United States, cat#L2KAP2).

## Extraction of RNA

Total RNA, including microRNA was isolated from HCC, HCV and control plasma samples using a mirVana™ PARISTM isolation kit (Ambion, Part Number AM1556) following the enrichment procedure for small RNAs purification according to the manufacturer's protocol [8]. Control samples were used to obtain the baseline for the genetic markers where controls represented by one fold. The concentration and purity of RNA were determined

by measuring the absorbance at 260 and 280nm using NanoDrop 2000A Spectrophotometer (ThermoScientific, USA).

## Real-Time PCR Quantification of miRNA Expression

The expressions of miRNAs were quantified according to the manufacturer's instructions by TaqMan miRNA assays (Applied Biosystems) following reverse transcription (Tiangen, Chin) of 40 ng RNA. Reactions were loaded onto a 96-well plate and run in duplicate on an ABI 7900 Fast Real-Time PCR System (Applied Biosystems). The reactions were firstly incubated at 50°C for 20 seconds and then 95°C for 15 minutes, followed by 40 cycles of denaturation at 94 °C for 15 seconds, then 30 seconds of annealing/extension at 55°C and finally 70 °C for 30 seconds. The  $\Delta\Delta CT$  method was used to determine the relative expression level (fold change) for miRNA143 and microRNA 550a [9]. The U6 was chosen as the endogenous normalizer. The primers used for qRT-PCR in this study are as following: miR-143: GCTGAGATGAAGCACTGAAGCTC, miR-550a: AGUGC CUGAGGGAGUAAGAGCCC and U6: CAAAGTCAGTGCAGG TAGGCTTA.

## Statistical Analysis

The statistical analyses in this study were performed using the Statistical Program for Social Sciences (SPSS) software 22.0 (SPSS Inc., Chicago, USA). Data were summarized as a mean  $\pm$  standard deviation. When  $P < 0.05$ , the difference was considered to have statistical significance. Receiver operating Characteristic (ROC) curves were constructed and area under curve (AUC) was calculated for detection of the sensitivity and specificity of miRNAs for predicting HCC cases among HCV-infected patients. Correlation between the miRNAs expression levels and other variables was determined using Spearman's correlation analysis.

## Results

The mean ages of the chronic hepatitis and HCC patients at diagnosis were  $58.4 \pm 8.5$  years,  $57.4 \pm 7.9$  years. There was no significant difference among the mean ages of the HCV and HCC groups ( $P=0.256$ ), (Tables 1-4) and (Figures 1-6).






Figure 1: Bar Chart presentation of the Child Pugh score across the two groups.

**Table 1:** demographic and laboratory variables presentation in the two groups.


Variable	HCC (37 patients) mean	HCC SD	HCV (41 patients) mean	HCV SD	P-value
miR-143	1.40	2.03	305.13	1630.81	0.920
miR-550	2.24	6.29	2162.63	5895.01	<0.001**
Age	57.47	7.97	58.42	8.52	0.256
ALT	58.59	67.42	30.31	18.55	0.002*
AST	139.32	395.10	46.53	28.24	0.001*
T.Bil	2.76	2.99	1.61	2.37	0.005*
Albumin	2.59	0.87	3.06	0.67	0.013*
INR	1.49	0.41	6.37	25.83	0.088
Platelets	128.46	65.81	120.46	55.92	0.781
AFP	3301.16	16858.57	10.68	14.89	0.001*




**Figure 2:** Micro RNA 143 level presented in box plot in the three groups.



**Figure 3:** Micro RNA 550 level presented in a box plot in the three groups.



**Figure 4:** Box plot presentation of AFP in the HCV and HCC groups.



**Figure 5:** ROC curve of miRNA 550 in relation to the presence of HCC.

**Biochemical Analysis:** The laboratory data of the included patients showed that there was a significant difference between the HCV and HCC groups as regards the ALT, AST, Albumin, Total Bilirubin and AFP (Table 1). When using the Child Pugh score as a predictive value for the occurrence of HCC; it was shown that its AUC was 0.67, NPV=56.4 and PPV=81.2, with sensitivity 43.3% and specificity 88% at a cut-off score 10 i.e. Child C (Table 2).

**Table 2:** Showing The Predictability Of HCC By mi550 And Child Pugh Score.

Variable	miR550	Child Pugh Score
Area under ROC (95% CI)	0.93 (0.86-0.99)	0.67 (0.525-0.812)
p-value (AUC=0.5)	<0.001**	0.032*
Positive prediction criterion (cutoff value)	≤3.29	Class C
Sensitivity (%)	91.89	43.33
Specificity (%)	90.24	88.00
PPV (positive predictive value)	89.5	81.2
NPV (negative predictive value)	92.5	56.4

**MiR-143 and miR-550a Expression in HCV and HCC and their use as Predictive Value for HCC Occurrence:** Plasma miR-143 should no significant difference between the two groups,

while miR-550a was significantly decreased in the HCC group versus the HCV group. This reveals that the miR-550a could be down-regulated by HCC. The predictive ability of miR-550a was assessed using regression and the AUC was 0.93 with PPV=89.5 and NPV=92.5, the sensitivity of the test was 91.89% and its specificity was 90.24% at a cut off value 3.29. (Figure 5) & (Table 2) Correlation between the two microRNAs markers used and various laboratory parameters revealed the following; that miR-143 was not correlated significantly with any laboratory parameter while miR-550a was correlated with AST, total bilirubin, albumin, INR, AFP and Child Pugh Score (Table 3). On the other hand, there was no relation between both markers and gender using the Mann Whitney test (Table 4).

**Table 4:** Relation with Gender Mann-Whitney.

	Mean Male (44 patients)	SD Male	Mean Female (19 patients)	SD Female	P-value
miR-143	284.66	1574.75	1.82	2.52	0.65
miR-550	1211.95	5488.52	8.02	21.49	0.899

**Discussion**

miR-143 is located in the chromosome 5 with a mature length of 22 [10]. A previous study has revealed that miR-143 exhibited down-regulation in many cancers such as colorectal cancer [11], pancreatic cancer [12] and lung cancer [13] in which miR-143 acts as a tumor suppressor inhibiting cell proliferation and inducing tumor cell apoptosis thus hindering the development of cancer [10]. miR-143 was exploited in many cancers e.g. lung cancer [14], gastric cancer [15], colorectal cancer [16], osteosarcoma [17], T-cell leukemia [18] and prostate cancer [19]. While some proposed the idea of a cancer suppression effect through mediators as IGF1 [11], matrix metalloprotease 13 [17] while others proposed the effect of miR-143 on ERK5 pathway increasing apoptosis [18,19] In the present study we found no correlation between miR-143 expression and occurrence of HCC in HCV infected patients, and this was in contrary to a recent study which showed that miR-143 was down-regulated in HCC patients [1].

First we have to mention that most studies that tackled this area concentrated mainly on the level of the micro RNA in the hepatocyte i.e. Histopathological and not the plasma level and this is an important differentiating point as serum level may be the higher with low cellular concentration and vice versa due to shedding from the cells. And to our knowledge all studies concerning miR-143 and miR-550a as markers for HCC used the hepatocyte level of miRNAs and not the serum form. This may because a great difference in results as the serum for could be affected by different factors like the amount of miRNA shedding from the cell or cellular destruction reflected on serum level, while factors like the actual cellular level may not be reflected. To our knowledge this is the first study to clear this point by measuring the serum not the cellular levels of miR-143 and miR-550a.

Second, miR-143 results could be explained by the fact that miR-143 was increased in patients that had recurrence or metastasis, as their study selected all stages of HCC, while our patients selection deferred in selecting patients with only non-metastatic HCC (although micro-metastasis could be present as apparent by the

**Table 3:** correlation between the microRNAs studied and various laboratory parameters.

Variable	miR550	Child Pugh Score
Area under ROC (95% CI)	0.93 (0.86-0.99)	0.67 (0.525-0.812)
p-value (AUC=0.5)	<0.001**	0.032*
Positive prediction criterion (cutoff value)	≤3.29	Class C
Sensitivity (%)	91.89	43.33
Specificity (%)	90.24	88.00
PPV (positive predictive value)	89.5	81.2
NPV (negative predictive value)	92.5	56.4

high AFP in some of the cases), so this could be a more appropriate marker for development of metastasis. In addition, it is important to note that while the difference in miR-143 was not significant between the HCV and HCC groups it was higher in the HCC group, which as revealed by the study mentioned above, the higher the miR-143 the better prognosis. On the other hand; this could also be explained by the hepatocyte destruction due to the HCC and hence higher level in the blood. Autophagy gene 2B (ATG2B) was found to be a possible target for miR-143, where miR-143 Overexpression is associated with down regulation of ATG2B [13]; thus decreasing the autophagy responsible for the cancer cell survival and inducing apoptosis [20].


The first study to investigate the role of miR-143 in HCC was done recently where the researchers exploited the different cellular pathways that could play important role in the HCC pathogenesis and found that GATA6 was the downstream target for miR-143, where its Overexpression will oppose the cancer suppressor effect of miR-143 thus increasing the tumor invasion in rats [21]. We found that the expression level of plasma miR-550a was significantly lower in HCC than HCV patients. This increased expression of miR-550a could be explained by its protective role in inhibiting cancer in the HCV group. A recent study revealed that; when injecting a mouse harboring cancer breast cells with miR-550a-p3, their metastatic ability is reduced. This was explained by the effect of miR-550a-p3 in down-regulating the ERK1 and ERK2 [22] (two important effector kinases in the oncogenic Ras/ERK pathway [23]).

In a study done by Tian et al. [24] on liver tissue with HCC they found that; miR-550a is responsible for the migration and vascular invasion of HCC cells, they proposed that this could be accomplished through its direct and functional target CPEB4, where the expression of the later is closely correlated with HCC treatment outcome [24] In addition, we conduct ROC analyses to detect the potential application of miR-550a in the diagnoses of HCC. Our results showed that miR-550a might be a potential serum biomarker for HCC. Moreover, The ROC curve analysis of miR550a showed the good sensitivity and specificity in differentiating



patients with HCC from those with HCV (Figure 5) & (Table 2). Another important finding is that serum miR-550a showed a statistically significant positive correlation with AST, total bilirubin, albumin, INR, AFP and Child Pugh Score (Table 3).

Finally, the Child Pugh score was a potential diagnostic marker for HCC (Table 2) & (Figure 6). This is in accordance with a lot of previous studies which showed that HCC is an important cause of sudden deterioration of liver function [25]. In conclusion, we suggest that plasma miR-550a might serve as a non-invasive diagnostic and prognostic serum marker of HCC, miR-550a was better than miR-143 in early diagnosis of HCC, although miR-143 needs more study on metastatic HCC for the evaluation of its effect on prognosis. Our study is limited by the small sample size and large-scale studies are in need for validation of our results.



**Figure 6:** ROC curve of Child Pugh score in relation to the presence of HCC.

## References

- Zhang J, Lin H, Wang XY, Zhang DQ, Chen JX, et al. (2017) Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma. *Cancer Biomark* 19(3): 257-262.
- El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, et al. (2014) Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. *World Journal of Hepatology* 6(11): 818-824.
- Shaker MK, Abdella HM, Khalifa MO, El Dorry AK (2013) Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. *Liver international: official journal of the International Association for the Study of the Liver* 33(10): 1601-1606.
- Hiotis SP, Rahbari NN, Villanueva GA, Klegar E, Luan W, et al. (2012) Hepatitis B vs. hepatitis C infection on viral hepatitis-associated hepatocellular carcinoma. *BMC Gastroenterology* 12: 64.
- Yu SJ (2016) A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. *Clinical and Molecular Hepatology* 22(1): 7-17.
- Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. *Nat Rev Cancer* 6(4): 259-269.
- Chen CJ, Lee MH (2011) Early Diagnosis of Hepatocellular Carcinoma by Multiple microRNAs: Validity, Efficacy, and Cost-Effectiveness. *Journal of Clinical Oncology* 29(36): 4745-4747.
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008) Circulating microRNAs as stable blood-based markers for cancer detection. *Proceedings of the National Academy of Sciences* 105(30): 10513-10518.
- Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. *Nature protocols* 3(6): 1101-1108.
- Liu X, Gong J, Xu B (2015) miR-143 down-regulates TLR2 expression in hepatoma cells and inhibits hepatoma cell proliferation and invasion. *Int J Clin Exp Pathol* 8(10): 12738-12747.
- Su J, Liang H, Yao W, Wang N, Zhang S, et al. (2014) MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. *PLoS one* 9(12): e114420.
- Masamune A, Nakano E, Hamada S, Takikawa T, Yoshida N, et al. (2014) Alteration of the microRNA expression profile during the activation of pancreatic stellate cells. *Scandinavian journal of gastroenterology* 49(3): 323-331.
- Wei J, Ma Z, Li Y, Zhao B, Wang D, et al. (2015) miR-143 inhibits cell proliferation by targeting autophagy-related 2B in non-small cell lung cancer H1299 cells. *Mol Med Rep* 11(1): 571-576.
- Ma Q, Jiang Q, Pu Q, Zhang X, Yang W, et al. (2013) MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. *Int J Biol Sci* 9(7): 680-692.
- Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, et al. (2009) Decreased expression of microRNA-143 and -145 in human gastric cancers. *Oncology* 77(1): 12-21.
- Zhang Y, Wang Z, Chen M, Peng L, Wang X, et al. (2012) MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. *Mol Cancer* 11: 23.
- Osaki M, Takeshita F, Sugimoto Y, Kosaka N, Yamamoto Y, et al. (2011) MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloproteinase-13 expression. *Mol Ther* 19(6): 1123-1130.
- Akao Y, Nakagawa Y, Iio A, Naoe T (2009) Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. *Leuk Res* 33(11): 1530-1538.
- Ahmad I, Singh LB, Yang ZH, Kalna G, Fleming J, et al. (2013) Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. *Br J Cancer* 108(1): 149-154.
- Kovaleva V, Mora R, Park YJ, Plass C, Chiramel AI, et al. (2012) miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells. *Cancer research* 72(7): 1763-1772.
- Xue F, Yin J, Xu L, Wang B (2017) MicroRNA-143 inhibits tumorigenesis in hepatocellular carcinoma by downregulating GATA6. *Exp Ther Med* 13(6): 2667-2674.
- Ho JY, Hsu RJ, Wu CH, Liao GS, Gao HW, et al. (2016) Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK 1 and 2. *Oncotarget* 7(33): 53853-53868.
- Busca R, Pouyssegur J, Lenormand P (2016) ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy? *Frontiers in cell and developmental biology* 4: 53.
- Tian Q, Liang L, Ding J, Zha R, Shi H, et al. (2012) MicroRNA-550a acts as a pro-metastatic gene and directly targets cytoplasmic polyadenylation element-binding protein 4 in hepatocellular carcinoma. *PLoS one* 7(11): e48958.
- Mazzanti R, Arena U, Tassi R (2016) Hepatocellular carcinoma: Where are we? *World Journal of Experimental Medicine* 6(1): 21-36.



**Assets of Publishing with us**

- Global archiving of articles
- Immediate, unrestricted online access
- Rigorous Peer Review Process
- Authors Retain Copyrights
- Unique DOI for all articles

<http://biomedres.us/>